

References ^{†A}

1. Keystone E, van der Heijde D, Mason D Jr, Landewé R, van Vollenhoven R, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheum* 2008;58:3319-29.
2. Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijckens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. *Ann Rheum Dis* 2009;68:797-804.
3. Fleischmann R, Vencovsky J, van Vollenhoven RF, Boronstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. *Ann Rheum Dis* 2009;68:805-11.

The T-score (**T**) is explained in 'New drugs: transparency', *Aust Prescr* 2009;32:80-1.

[†] At the time the comment was prepared, a scientific discussion about this drug was available on the website of the European Medicines Agency (www.ema.europa.eu).

^A At the time the comment was prepared, information about this drug was available on the website of the Therapeutic Goods Administration (www.tga.gov.au/pmeds/auspar.htm)

Corrections

New drugs: Nebivolol (*Aust Prescr* 2010;33:55-6)

Following receipt of correspondence, which is published on pages 101-2 in this issue, the New drug comment on nebivolol has been corrected as follows.

In paragraph 6 the third sentence has been deleted ('This was a *post hoc* analysis ... different doses of nebivolol.')

Also in paragraph 6, the fifth sentence ('The target dose ... compared to placebo.') has been corrected to 'The target dose was reached by two-thirds of the patients in the nebivolol group. Nebivolol was associated with a significant reduction (absolute risk reduction of 4.2%) in the composite end point of all-cause mortality or hospitalisation (due to a cardiovascular event), compared to placebo.'

Reference 5 has been replaced by

5. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al.; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005;26:215-25.

New drugs: Miglustat (*Aust Prescr* 2010;33:92-3)

Paragraph 4 should start 'Regular intravenous infusion of recombinant glucocerebrosidase ...'.

Self-test questions (*Aust Prescr* 2010;33:84-7)

Questions 1 and 2 on page 87 should be 3 and 4.

Answers to self-test questions

- | | | | |
|----------|----------|---------|---------|
| 1. False | 3. False | 5. True | 7. True |
| 2. False | 4. False | 6. True | 8. True |

www.australianprescriber.com

Australian Prescriber is available on the internet in full text, free of charge. On the homepage, go to **Free subscription**, then **Email alert** to be sent the contents of the latest issue when it is published online.

Australian Prescriber mailing list

Australian Prescriber is distributed every two months, free of charge, to medical practitioners, dentists and pharmacists in Australia, on request. Subscribe online at www.australianprescriber.com (go to **Free subscription**, then **Paper copy**) or send in this form.

Tick whichever of the following apply:

I have access to the *Australian Prescriber* website on the internet Yes No

- Place me on the mailing list
 Delete me from the mailing list
 Change my address
 Send me the available back issues

Name:

Ref no.:
(on the address sheet above name)

Address:
.....

Profession:
(general practitioner, resident, etc.)

Postal: *Australian Prescriber* Mailing Service
GPO Box 1909
CANBERRA ACT 2601

Telephone: (02) 6241 6044 Fax: (02) 6241 4633

Online: www.australianprescriber.com (go to
Free subscription, then **Paper copy**)

See Privacy notice at www.australianprescriber.com/content/privacynotice

Editorial office

For general correspondence such as Letters to the Editor, contact the Editor.

Telephone: (02) 6202 3100 Fax: (02) 6282 6855

Postal: The Editor
Australian Prescriber
Suite 3, 2 Phipps Close
DEAKIN ACT 2600

Email: info@australianprescriber.com

Website: www.australianprescriber.com